Common variable immunodeficiency

• Prophylactic antibiotics for patients with recurrent sinopulmonary infections. Evidence in support of this approach is largely derived from benefits observed in retrospective studies of children with this and similar antibody deficiencies.

Common variable immunodeficiency
ICD-10	D83
ICD-9	279.06
OMIM	240500
DiseasesDB	3274
MeSH	D017074

WikiDoc Resources for Common variable immunodeficiency
Articles
Most recent articles on Common variable immunodeficiency Most cited articles on Common variable immunodeficiency Review articles on Common variable immunodeficiency Articles on Common variable immunodeficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Common variable immunodeficiency Images of Common variable immunodeficiency Photos of Common variable immunodeficiency Podcasts & MP3s on Common variable immunodeficiency Videos on Common variable immunodeficiency
Evidence Based Medicine
Cochrane Collaboration on Common variable immunodeficiency Bandolier on Common variable immunodeficiency TRIP on Common variable immunodeficiency
Clinical Trials
Ongoing Trials on Common variable immunodeficiency at Clinical Trials.gov Trial results on Common variable immunodeficiency Clinical Trials on Common variable immunodeficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Common variable immunodeficiency NICE Guidance on Common variable immunodeficiency NHS PRODIGY Guidance FDA on Common variable immunodeficiency CDC on Common variable immunodeficiency
Books
Books on Common variable immunodeficiency
News
Common variable immunodeficiency in the news Be alerted to news on Common variable immunodeficiency News trends on Common variable immunodeficiency
Commentary
Blogs on Common variable immunodeficiency
Definitions
Definitions of Common variable immunodeficiency
Patient Resources / Community
Patient resources on Common variable immunodeficiency Discussion groups on Common variable immunodeficiency Patient Handouts on Common variable immunodeficiency Directions to Hospitals Treating Common variable immunodeficiency Risk calculators and risk factors for Common variable immunodeficiency
Healthcare Provider Resources
Symptoms of Common variable immunodeficiency Causes & Risk Factors for Common variable immunodeficiency Diagnostic studies for Common variable immunodeficiency Treatment of Common variable immunodeficiency
Continuing Medical Education (CME)
CME Programs on Common variable immunodeficiency
International
Common variable immunodeficiency en Espanol Common variable immunodeficiency en Francais
Business
Common variable immunodeficiency in the Marketplace Patents on Common variable immunodeficiency
Experimental / Informatics
List of terms related to Common variable immunodeficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mohsen Basiri M.D.

Synonyms and keywords: CVID; common variable hypogammaglobulinaemia; non-familial hypogammaglobulinaemia; acquired hypogammaglobulinemia; immunodeficiency, common variable; late-onset immunoglobulin deficiency

Overview

Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder. It is the most common form of severe antibody deficiency affecting both children and adults. The characteristic immune defect in CVID is impaired B cell differentiation with defective production of immunoglobulin. CVID is defined by low total serum concentrations of immunoglobulin G (IgG), as well as low immunoglobulin A (IgA) and/or immunoglobulin M (IgM), poor or absent response to immunization, and the absence of any other defined immunodeficiency state.

Most patients are diagnosed between the ages of 20 and 40 years. Delayed recognition is common.

Bacterial infections of the sinopulmonary tract, particularly sinusitis and pneumonia, are experienced by most patients with CVID. Opportunistic and unusual infections are uncommon, but do occur.

In addition to recurrent infections, patients with CVID have evidence of immune dysregulation leading to autoimmunity, a variety of inflammatory disorders, and malignant disease. Patients may suffer from chronic lung disease, gastrointestinal and liver disorders, granulomatous infiltrations, lymphoid hyperplasia, splenomegaly, or malignancy.

Various forms of primary and secondary hypogammaglobulinemia must be excluded before the diagnosis of CVID can be assigned.The diagnosis of CVID requires a suggestive clinical history, a reduced total serum concentration of IgG, plus low IgA or IgM, and poor responses to both protein- and polysaccharide-based vaccines.

Historical Perspective

In 1953, Charles Janeway was the first to describe the first case of CVID. The case was a 39-year-old who had recurrent infections, bronchiectasis, and meningitis. However described in 1953, there were no standard criteria for CVID which caused confusion during diagnosis. In the decade from the 1990s, the European Society for Immunodeficiency (ESID) and Pan-American Group for Immunodeficiency (PAGID) determined diagnostic criteria, including minimum age of diagnosis and the need to rule out other diseases, to determine the disease. These criteria were published in 1999 and since that time, some aspects, like increasing the minimum age, have been modified.

Classification

Common variable immunodeficiency (CVID) is a heterogeneous immune disorder characterized by recurrent sinopulmonary infections, autoimmune diseases, granulomatous disease, and an enhanced risk of malignancy.

A phenotypic approach to clssify CVID has been suggested, based upon the type of complications the patient demonstrates. This method is from an analysis of the European Common Variable Immunodeficiency Disorders registry, in which 334 patients with CVID were followed for an average of 26 years . Five phenotypic categories were proposed:

1. Patients with no complications.
2. Patients with autoimmune disease.
3. Patients with lymphocytic organ infiltration i.e. lymphocytic enteropathy, granulomas, unexplained hepatomegaly, persistent lymphadenopathy, splenomegaly.
4. Patients with predominant enteropathy
5. Patients with lymphoid malignancy

Pathophysiology

The exact pathophysiology of CVID is not fully understood. CVID is a group of disorders with a common endpoint of defective immunoglobulin secretion and dysregulated immune functions. The clinical dissimilarity of CVID proposes that multiple immunoregulatory dysfunctions can result in the final common pathway of hypogammaglobulinemia.

The immune defect in CVID is due to defective B cell differentiation into plasma cells, with the inability to produce immunoglobulin. CVID is associated with a high occurrence of autoimmune, inflammatory, and malignant disorders, whereas these conditions are not observed in X-linked agammaglobulinemia (XLA), a disease that affects early B cell development.

CVID appears to result from a number of gene defects. which may be either recessive in inheritance or autosomal dominant with variable penetrance. Some of these are due to defects of B cell signalling molecules but additional genes affecting immune regulation may also lead to the CVID phenotype.

Type	Gene	Immunoglobulin Deficiency	Phenotype
ICOS deficiency	ICOS	Low IgG and IgA	Recurrent infections, autoimmunity, gastroenteritis.
CD19 deficiency	CD19	Low IgG and IgA	Recurrent infections. May be associated with glomerulonephritis.
CD81 deficiency	CD81	Low IgG, low or normal IgA and IgM	Recurrent infections. May be associated with glomerulonephritis.
CD20 deficiency	CD20	Low IgG, normal or elevated IgM, and IgA	Recurrent infections.
CD21 deficiency	CD21	Low IgG; impaired antipneumococcal response	Recurrent infections.
TACI deficiency	TNFRSF13B	Low IgG and IgA and/or IgM	Variable clinical expression
BAFF-receptor deficiency	TNFRSF13C	Low IgG and IgM	Variable clinical expression
TWEAK deficiency	TWEAK	Low IgM and IgA; lack of antipneumococcal antibody	Recurrent infections such as Pneumonia, bacterial infections, warts; and thrombocytopenia; neutropenia
NF-kappa-B2 deficiency	NFKB2	Low IgG and IgA and IgM; very low B cells in some	Recurrent infections; adrenal insufficiency; ACTH deficiency; alopecia
NF-kappa-B1 deficiency	NFKB1	Low IgG and IgA and IgM; low B cells in some	Recurrent infections
IKAROS	IKZF1	Low IgG and IgA and IgM, very low B cells	Recurrent infections

Causes

The cause of common variable immunodeficiency has not been identified. Genetic mutations can be recognized as the cause of CVID in about 10% of patients, and familial inheritance accounts for 10-25% of the affected population. Rather than arising from a single genetic mutation, CVID is due to numerous mutations that all are associated with dysfunction in antibody regulation and production.

Differentiating Common Variable Immunodeficiency from other Diseases

CVID should be differentiated from the following diseases:

• Bruton agammaglobulinemia(X-linked agammaglobulinaemia)
• Severe combined immunodeficiency(SCID)

Epidemiology and Demographics

Prevalence

CVID has an estimated prevalence ranging from a low of 2 per 100,000 to a high of 4 per 100,000 with an average of 3 per 100,000.

Age

• The typical patient is after puberty and between 20 and 40 years age.
• About 20% of patients are diagnosed in childhood.
• In an analysis of the CVID data from the ESID about 35 percent of patients were diagnosed before 10 years of age; and in studies from United States centers, 20 percent of patients are diagnosed before the age of 20 years. The majority of patients are diagnosed between the ages of 20 and 45.

Gender

There is no gender predilection to common variable immunodeficiency.

Race

Race is not associated with an increased risk of common variable immunodeficiency. However, there is some evidence of higher prevalence among individuals of northern European descent.

Natural History, Complications and Prognosis

Natural History

All patients have several histories of acute and recurrent infections. The majority of patients with CVID have evidence of immune dysregulation leading to autoimmunity, inflammatory disorders, and malignant disease. Accordingly, CVID Patients may suffer from chronic lung disease, gastrointestinal and liver disorders, granulomatous infiltrations of several organs, lymphoid hyperplasia, splenomegaly, or malignancy.The clinical manifestations of CVID affect multiple organ systems, and patients often have the history of several specialists visits by the time they are recognized. It may be partly for this reason, delayed diagnosis of this condition is common. in the European Society for Immunodeficiencies (ESID) database, and other studies, there was an average of five to seven years between the beginning of symptoms and diagnosis

Complications

Numerous complications are possible in CVID. They include:

• Recurrent infections in the sinopulmonary, gastrointestinal, septic arthritis, bacterial meningitis/sepsis
• Autoimmune phenomena - Vitiligo, autoimmune hepatitis, primary biliary cirrhosis, hemolytic anemia
• Malignancy - Lymphomas, gastric cancer, malignant melanoma
• Rheumatoid arthritis
• Vitiligo
• Thrombocytopenia
• Neutropenia
• Hemolytic anemia
• Pernicious anemia
• Malabsorption
• Autoimmune hepatitis
• Primary biliary cirrhosis
• Atrophic gastritis
• The mainstay of treatment for Inflammatory bowel disease

Prognosis

Prognosis with the advent of immune globulin treatment is generally good, and the incidence of death associated with acute bacterial infection in CVID decreased dramatically. Afterwards, the leading causes of death are owing to complications of chronic lung disease and malignancies.

In the several large series of following patients with CVID, the leading causes of death were respiratory failure due to bronchiectasis, lymphoma, and liver disease.

Diagnosis

History and Symptoms

Symptoms of CVID are:

• Polyarthritis, or joint pain, spread across most joints, but specifically fingers, wrists, elbows, toes, ankles and knees
• Chronic infections (most common symptom) specifically upper respiratory tract infection - e.g. bronchitis, sinusitis which respond to antibiotics but return or reoccur. Common infective organisms include:
  • Haemophilus influenzae
  • Streptococcus pneumoniae
  • Moraxella catarrhalis
  • Staphylococcus aureus
• Viral infections that usually respond to antivirals, (URTIs), sinusitis, tonsilitis, epiglottitis, dermatological abscesses/boils (often, but not exclusively, facial and axillary), pneumonia, bronchitis, pleurisy, stomach/intestinal infections, colds, influenza, shingles, conjunctivitis
• Tiredness
• Shortness of breath - due to bronchiectasis (lung tissue damage as a result of repeated chest infections)
• Patients may lose weight
• Children may show a "failure to thrive" - they may be underweight and underdeveloped compared with "normal" peers
• Diarrhoea and malabsorption - due to villous atrophy in the small intestine, which can resemble coeliac disease, intestinal infections, including protozoan and parasitic infections, bacterial overgrowth of the intestine
• Increased incidence of inflammatory bowel disease
• Abdominal pain, bloating, nausea, vomiting, diarrhea, weight loss.

Physical Examination

Head

• Swelling of the lymph glands - lymphadenopathy

Abdomen

• Enlarged spleen

Laboratory Findings

• Complete blood count and differential count - lymphocytopenia
• Blood culture
• Hypogammaglobulinemia, or low levels of immunoglobulin G (IgG), IgA and/or IgM. Lack of normal levels of antibody in the serum is part of the diagnosis
• Poor titer levels in response to vaccination. Responsiveness may be tested after administration of polysaccharide and non-polysaccharide coated pathogens (e.g. streptococci and tetanus respectively)

Diagnosis is often delayed; and diagnosis is often made in the second or third decade of life after referral to an immunologist. As with several other immune cell disorders, CVID may predispose to lymphoma or possibly stomach cancer. There also appears to be a predilection for autoimmune diseases, with a risk of up to 25%. Autoimmune destruction of platelets or red blood cells are the commonest of these.

Treatment

Medical Therapy

• Immune Globulin Replacement Therapy

The mainstay of treatment for CVID is immune globulin replacement therapy. In addition, management requires precise monitoring for associated conditions, such as sinopulmonary, granulomatous, gastrointestinal, and autoimmune diseases, and malignancy.<ref>Charlotte Cunningham-Rundles (2010). "How I treat common variable immune deficiency". Blood. 116 (1): 7–15. doi:10.1182/blood-2010-01-254417. PMID 20332369. </ref>

Treatment

The mainstay of treatment for CVID is Immune globulin replacement therapy, an injection of human antibodies harvested from blood donations which may be administered either intravenously or subcutaneously:

• Intravenous immunoglobulin (IVIG, most common treatment) .The routine initial dosing for IVIG is 300 to 600 mg/kg every three to four weeks.
• Subcutaneous immunoglobulin G (SCIG, relatively new therapy), As an alternative to IVIG which is usually administered weekly or every other week. Dose depends on body weight and immune globulin requirements.
• Intramuscular immunoglobulin (IMIG, less effective, painful).

Immune globulin replacement therapy reduces the number of infections and decreases antibiotic use and hospitalizations. This therapy is not a cure, but it strengthens immunity in hypogammaglobulinemic patients, which helps to prevent recurrent upper respiratory infections, and fewer serious infections and days of hospitalization among patients with primary immunodeficiency . However, immune globulin therapy does not completely eliminate infections in most patients, and the sinopulmonary and gastrointestinal systems, in particular, remain susceptible.

IG therapy should not be used if the patient has anti-IgA antibodies but in these cases, products low in IgA can be used; subcutaneous delivery also is a means of permitting such patients to have adequate antibody replacement.

IVIG treatment can be received by patients with a complete IgA deficiency if the IgA is completely removed from the treatment.

Some CVID patients may experience reactions to IG therapies; reactions may include:

• Anaphylactic shock (very rare)
• Hives (rare)
• Difficulty breathing
• Headache (relatively common, may be relieved by an antihistamine, paracetamol / acetaminophen, or an anti-inflammatory (naproxen, advil, aspirin)
• Nausea (common)
• Fever (common)
• Aseptic meningitis (rare)
• Severe fatigue
• Muscle aches and pain, or joint pain
• Thrombotic events (rare)

Reactions can be minimized by taking an antihistamine and/or hydrocortisone and some paracetamol/acetaminophen/anti-inflammatory (naproxen, advil, aspirin) prior to treatment; patients should also be thoroughly hydrated and continue to drink water before, after and during treatment (if possible).

• Antimcrobial Therapy

Antibiotics may be administered prophylactically, as well as for the treatment of acute infections or exacerbations of chronic infections.

• Prophylactic antibiotics do not routinely administer to all patients with CVID. In CVID patients with ongoing lung disease, and with recurrent sinopulmonary infections, this approach is helpful.
• Antibiotics are required for management of acute infections among patients with immunodeficiency. CVID patients typically do not clear common infections without the use of proper antibiotics. Thus, immediate recognition and treatment with antibiotics can help prevent chronic infections and infectious complications. It is important to ensure that the infection has treated completely at the end of a course of antibiotics, as patients with immunodeficiency sometimes necessitate longer duration of therapy. Antibiotic resistance does not seem to be a serious problem in patients with CVID, for causes which are not clearly understood, then the same antibiotics continue to be useful, regardless of prolonged or frequent exposure.

Prevention

• There are no primary preventive measures available for common variable immunodeficiency.
• Secondary and tertiary prevention strategies following CVID include avoidance measures, vaccination, prophylactic antibiotics, immune globulin therapy, and when infections do occur, broader spectrum and more prolonged antibiotics are often recommended.
• Avoidance: to reduce exposure to others with potentially contagious illnesses: proper hand-washing and use of alcohol-based disinfectants should be provided to patients and their families; Co-sleeping among family members should be minimized, and immunization of family members and close contacts is required.
• Careful attention should be paid to patient's oral hygiene and dental health.
• The efficiency of killed or inactivated vaccines in patients with CVID has not been evaluated extensively. It means patients with CVID have impaired responses to vaccination, however, vaccination might augment T cell immunity to viral agents, in addition to inducing the formation of specific antibodies. Certain live vaccines i.e. oral polio, smallpox, live-attenuated influenza vaccine, yellow fever, or live oral typhoid vaccines should not be given to patients with CVID , particularly those with significantly impaired T cell function.

External links

• Primary Immunodeficiency Association (UK)
• Immune Deficiency Foundation (US)
• Immune Deficiencies Foundation of Australia
• Immune Deficiencies Foundation of New Zealand
• IPOPI (International Patient Organisation for Patients with Primary Immunodeficiency)
• Canadian Immunodeficiencies Patient Organization (Canada)

Template:WikiDoc Sources